Tenon Medical, Inc. (TNON)
NASDAQ: TNON · Real-Time Price · USD
2.470
-0.330 (-11.79%)
At close: Mar 28, 2025, 4:00 PM
2.355
-0.115 (-4.64%)
Pre-market: Mar 31, 2025, 7:57 AM EDT
Company Description
Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico.
The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.
Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Tenon Medical, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 27, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Steven Foster |
Contact Details
Address: 104 Cooper Court Los Gatos, California 95032 United States | |
| Phone | 408-649-5760 |
| Website | tenonmed.com |
Stock Details
| Ticker Symbol | TNON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001560293 |
| CUSIP Number | 88066N303 |
| ISIN Number | US88066N3035 |
| Employer ID | 45-5574718 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Foster | Chief Executive Officer, President and Director |
| Richard Ginn | Founder, Chief Technology Officer and Director |
| Kevin Williamson | Chief Financial Officer |
| Richard M. Ferrari | Founder and Executive Chairman |
| Steve Moscaret | Senior Vice President of Sales and Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 424B5 | Filing |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 12, 2025 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 4, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |